论文部分内容阅读
目的:观察雷替曲塞联合奥沙利铂方案治疗术后复发转移性食管癌的近期疗效和不良反应。方法:将76例术后复发转移性食管癌患者随机分为观察组与对照组。观察组给予雷替曲塞联合奥沙利铂方案化疗,对照组给予氟尿嘧啶/左亚叶酸钙联合奥沙利铂方案。两方案每3周为1个周期,每2个周期后行CT检查评价疗效及毒副反应,最多化疗6个周期。结果:全部76例患者均可评价疗效及不良反应,两组患者在有效率、临床获益率和中位生存期方面比较差异均无统计学意义(P>0.05)。观察组患者在严重骨髓抑制、胃肠道反应、静脉炎的发生率方面比对照组低,二者比较差异有统计学意义(P<0.05);两组患者在神经毒性、转氨酶异常及其他化疗反应的发生率上无显著性差异(P>0.05)。结论:雷替曲塞联合奥沙利铂方案治疗术后复发转移性食管癌的有效率和中位生存时间与氟尿嘧啶/亚叶酸钙联合奥沙利铂方案相当,化疗周期短、部分毒副反应轻,值得在临床上推广应用。
Objective: To observe the short-term efficacy and side effects of ralterexed combined with oxaliplatin in the treatment of recurrent esophageal cancer after operation. Methods: 76 patients with recurrent esophageal cancer were randomly divided into observation group and control group. The observation group received raltitrexed plus oxaliplatin regimen and the control group received fluorouracil / levofloxacin plus oxaliplatin regimen. The two programs every 3 weeks for a cycle, every 2 cycles after the CT evaluation evaluation of efficacy and side effects, up to 6 cycles of chemotherapy. Results: All 76 patients were evaluated for efficacy and adverse reactions. There was no significant difference in efficiency, clinical benefit rate and median survival between the two groups (P> 0.05). Compared with the control group, the incidence of severe myelosuppression, gastrointestinal reaction and phlebitis in the observation group was lower than that in the control group (P <0.05). The neurotoxicity, aminotransferase abnormalities and other chemotherapy No significant difference in the incidence of response (P> 0.05). CONCLUSION: The efficacy and median survival time of raltettrose combined with oxaliplatin in the treatment of postoperative recurrent esophageal cancer is comparable to that of fluorouracil / leucovorin combined with oxaliplatin. The chemotherapy cycle is short and some toxicities and side effects Light, it is worth promoting in clinical application.